Basic Information
GeneXpert for MTB RIF
A Rapid cost effective RT-PCR for detection of MTB Rifampicin Resistance
GeneXpert a CBNAAT system from Cepheid for MTB, MDR
Specimen Machine Printout
MTB NOT DETECTED
Specimen Machine Printout
MTB DETECTED LOW; RIF Resistance NOT DETECTED
GeneXpert Ultra represent a remarkable advancement in the diagnosis and treatment of tuberculosis (TB), a major global health concern. These cutting-edge diagnostic technologies, developed by Cepheid, have revolutionized the field by providing rapid and accurate detection of TB and its drug-resistant forms, leading to timely interventions and improved patient outcomes. Specimen:Site Specific Pulmonary:Sputum & Bronchial Aspirate etc. Extra-pulmonary:Pus, Body Fluids, FNA, Biopsy etc. Xpert MTB/RIF GeneXpert Ultra is designed to detect Mycobacterium tuberculosis (MTB) and determine rifampicin resistance, a key indicator of multidrug-resistant TB (MDR-TB). It employs real-time polymerase chain reaction (PCR) technology to amplify and detect specific DNA sequences in TB bacteria. Its exceptional sensitivity allows it to detect very low levels of MTB DNA, even in challenging cases like paucibacillary or extrapulmonary TB. With results available within just 2 hours, it enables healthcare providers to initiate treatment promptly, reducing transmission risk. Moreover, it identifies rifampicin resistance, guiding appropriate drug regimens. Summary: The impact of these technologies on TB management is profound. They enable early diagnosis, rapid drug resistance identification, effective infection control, reduced mortality rates, and remarkable sensitivity and specificity. In summary, GeneXpert uses MTB-RIF Ultra as a game-changer. It works as a pivotal tool in the fight against TB, significantly improving diagnostic accuracy, patient care, and disease control efforts on a global scale.
Under the National Tuberculosis Elimination Programme, it is mandatory for all medical laboratories and treating physicians to register the complete details of all MTB-positive patients on the NIKSHAY portal. 35